Combined Therapy of anti-cd20 Antibody with an inhibitor of bcl-2, an inhibitor of MDM2, method of treatment, use

摘要

Combined Therapy of anti-cd20 Antibody with an inhibitor of bcl-2 and MDM2 inhibitor for the treatment of cancer, especially in the Combined Therapy of cancers that Express CD20 with an anti-cd20 Antibody of Type 1 or LY1 Humanized Antibody B - and not fucosilado inhibitor B CL - 2 and an inhibitor of MDM2.Claim 1: anti-cd20 Antibody for Cancer Treatment in combination with an inhibitor of bcl-2, an inhibitor of MDM2. Claim 5: Antibody according to any one of claims 1 to 4, characterized in that said not fucosilado anti-cd20 Antibody is an Antibody (LY1 Humanized.Claim 6: The Antibody according to any one of claims 1 to 5, characterized in that said anti-cd20 Antibody is not fucosilado obinutuzumab. Claim 7: Antibody according to any one of claims 1 to 5, characterized in that the anti-cd20 Antibody rituximab Type I is.Claim 8: The Antibody according to any one of claims 1 to 7, characterized in that the inhibitor of bcl-2 is 4 - (4 - [2 - (4-chlorophenyl) - 4.4 - dimetilciclohex - 1 - 1 - il] methyl} piperazin-1-yl) - 2 - (1h pyrrolo [2,3-b] pyridin - 5 - iloxi) - N - [4 - [(Tetrahydro - 2H - piran - 4 - methyl) amino] - 3 - [(trifluoromethyl) sulfonyl] phenyl] sulfonyl) benzamide.Claim no. 9: The Antibody according to any one of claims 1 to 7, characterized in that the MDM2 inhibitor is acid, 4 - [(2R, 3S, 4R, 5S) - 4 - (2 - Chloro - fluoro - phenyl) - 3 - (3 - Chloro - fluoro - 2 - cyano - 4 - phenyl) - 5 - (2,2-dimethyl - propyl) pyrrolidin-2-one carbonyl] amino} - 3 - metoxibienzoico.Claim 1: a Pharmaceutical composition comprising a combination of an anti-cd20 Antibody Type I or a B - LY1 Humanized Antibody that is without fucosilar fucose with a quantity of 60% or less of the total amount of Oligosaccharides (Sugars) in asn297, and 4 - (4 - [2 - (4 - clo Rofenil) - 4.4 - dimetilciclohex - 1 - 1 - il] methyl} piperazin-1-yl) - 2 - (1h pyrrolo [2,3 - B] pyridin - iloxi) - 5 - (N - (4 - [(Tetrahydro - 2H - piran - 4 - methyl) amino] - 3 - [(trifluoromethyl) sulfonyl] phenyl] sulfonyl) benzamide and acid, 4 - [(2R, 3S, 4R, 5S) - 4 - (4 - Chloro - fluoro - 2 - phenyl) - 3 - (3 - Chloro - fluoro - 2 - phenyl) - 5 - (4 - cyano - 2,2-dimethyl - propyl) pyrrolidin-2-one carbonyl] amino} - 3 - metoxibenzoico or a Salt of the same For the treatment of cancer.